SpringWorks Therapeutics, Inc. Overview
Pro stress-test →SpringWorks Therapeutics is a commercial-stage biopharmaceutical company that develops and delivers precision medicine for cancer treatment. The company is a healthcare company of Merck KGaA, Darmstadt, Germany, following an acquisition agreement announced in April 2025. SpringWorks has commercialized the first and only FDA and EC approved medicine for adults with desmoid tumors and the first and only FDA and EC approved medicine for both adults and children with neurofibromatosis type 1 associated plexiform neurofibromas.
Strategic Profile
Pro stress-test →The company's model is specialty-first: concentrate on severe, underserved tumor types; build clear clinical value around measurable outcomes; and execute launches through focused field teams that operate in specialist centers. SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types.
Competitive Landscape
Pro stress-test →SpringWorks' top competitors include Aptadel Therapeutics, Mesentech, and QSAM Biosciences. The company competes in the rare tumor and targeted oncology space, where it holds a differentiated position through approved products in desmoid tumors and neurofibromatosis type 1. Within the broader precision medicine oncology market, it faces competition from larger pharma companies with broader pipeline portfolios.
Industry Context
SpringWorks Therapeutics, Inc. operates in Rare tumor targeted oncology.
Key facts
Founded: 2017 · Headquarters: Stamford, Connecticut, US · Employees: 382 (as of May 31, 2026) · Revenue: Hundreds of millions (from approved products as of 2026)